Jose L. Bada-Rodriguez
Malaga, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 25, 2024
Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations.
Journal: Frontiers in immunology
Published: June 19, 2023
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Journal: Frontiers in immunology
Published: September 16, 2021
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.
Journal: Journal of clinical medicine
Published: March 05, 2020
Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.
Journal: Scientific reports
Published: August 08, 2017
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.
Journal: PloS one
Published: October 06, 2016
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 11, 2016
Prevalence and clinical relevance of local allergic rhinitis.
Journal: Allergy
Published: July 13, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026